Holen Sie sich die Stockscreener-App
36.84
0.26%
0.0704
Schlusskurs vom Vortag:
$36.77
Offen:
$36.48
24-Stunden-Volumen:
359.91K
Relative Volume:
0.50
Marktkapitalisierung:
$15.58B
Einnahmen:
$5.81B
Nettoeinkommen (Verlust:
$412.00M
KGV:
39.19
EPS:
0.94
Netto-Cashflow:
-
1W Leistung:
+0.89%
1M Leistung:
+1.50%
6M Leistung:
+28.81%
1J Leistung:
+45.83%
1-Tages-Spanne:
$36.46
$37.05
1-Wochen-Bereich:
$35.73
$37.05
52-Wochen-Spanne:
$23.69
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Firmenname
Smith Nephew Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
36.85 | 15.58B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
125.32 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.51 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.56 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.09 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.05 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-03-12 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-06 | Herabstufung | Berenberg | Buy → Hold |
| 2024-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-10-13 | Eingeleitet | Stifel | Hold |
| 2023-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2023-04-27 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Eingeleitet | Citigroup | Buy |
| 2022-11-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-04 | Hochstufung | Redburn | Sell → Neutral |
| 2021-06-09 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Eingeleitet | Barclays | Overweight |
| 2020-07-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-21 | Eingeleitet | Citigroup | Buy |
| 2019-11-12 | Eingeleitet | Bernstein | Outperform |
| 2019-07-23 | Hochstufung | Berenberg | Hold → Buy |
| 2019-02-08 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-27 | Herabstufung | Goldman | Buy → Neutral |
| 2017-01-19 | Eingeleitet | HSBC Securities | Hold |
| 2016-12-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Herabstufung | Berenberg | Buy → Hold |
| 2016-02-26 | Eingeleitet | Cantor Fitzgerald | Hold |
Alle ansehen
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Joint Reconstruction Devices Market 2025-2032: New Technologies are Transforming the Landscape, Reaching $149 Billion by 2032 - GlobeNewswire Inc.
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Sequoia Financial Advisors LLC Has $357,000 Stock Holdings in Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
Smith & Nephew (LON:SN) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Smith & Nephew expands its advanced bioactives portfolio - MarketScreener
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant - Ariva
Smith & Nephew Aligns Director Compensation with Shareholder Interests - The Globe and Mail
Smith & Nephew (LON:SN) Insider Simon Lowth Purchases 355 Shares - Defense World
Smith & Nephew (LON:SN) Insider Katarzyna Mazur Hofsaess Purchases 541 Shares of Stock - Defense World
Scharf ETF Holdings - Quiver Quantitative
FMI Global Equity Q2 2025 Review - Seeking Alpha
FMI All Cap Equity Q2 2025 Review - Seeking Alpha
FMI Large Cap Equity Q2 2025 Review (Mutual Fund:FMIHX) - Seeking Alpha
Smith & Nephew director David King buys USD100,000 in shares - MarketScreener
Smith & Nephew stock hits 52-week high at 36.56 USD - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Smith & Nephew (LON:SN) Stock - Defense World
Smith & Nephew Earnings: The Turnaround Started Three Years Ago and Now Bears Fruit - Morningstar
Smith & Nephew's Turnaround Pushes Profitability Higher - Morningstar
Smith & Nephew plc ADR: Rising 11.43% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Smith & Nephew SNATS, Inc. (SNN) Stock Forecasts - Yahoo Finance
What Are Expectations For Smith & Nephew plc ADR (NYSE: SNN) In The Short Term? - stocksregister.com
Upwork Inc (NASDAQ: UPWK) Is Down -0.17% – Is It A Buying Opportunity? - stocksregister.com
FTSE 100 today: Index inches higher; BP beats, Smith & Nephew rallies - Investing.com
Is Smith & Nephew PLC (LSE:SN) Elevating FTSE 100 Surgical Innovation? - Kalkine Media
Smith & Nephew schedules release of second quarter and half-year 2025 results - Investing.com
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Bank of New York Mellon Corp - Defense World
Validea's Top Health Care Stocks Based on Martin Zweig - AInvest
SNN’s 2023 Market Dance: Up 12.53% – Time to Invest? - investchronicle.com
Bessemer Group Inc. Purchases 1,701 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) - Defense World
Smith & Nephew’s Role in the FTSE 100 Healthcare Segment - Kalkine Media
Smith & Nephew (LON:SN) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Smith & Nephew appoints new Non-Executive Director - Investing.com
حصلت شركة سميث+نيفيو على عقد لتوفير أنظمة علاج الجروح بالضغط السلبي لوزارة الدفاع الأمريكية - Sahm
Smith & Nephew plc: Institutional Strength and Dividend Discipline Fuel Undervalued Gem - AInvest
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹ - The Globe and Mail
Shell Plc Declares Q1 2025 Dividend - DirectorsTalk Interviews
Smith+Nephew reports solid Q1 2025 growth - Investing.com
Smith+Nephew schedules Q1 2025 trading report release - Investing.com
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Finanzdaten der Smith Nephew Plc Adr-Aktie (SNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):